Our data highlight that further work is required to determine the exact mechanisms by which mutant human DAT, and Arg445Cys in particular, lead to disease and the newly identified DTDS clinical phenotypes, such as further investigation of undetermined effects of structure, aberrant DAT folding and oligomerization defects. Here, SLC6A3 is linked to SLC6A3-related dopamine transporter deficiency syndrome.